Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 1
1992 2
1993 2
1994 1
1995 2
1997 1
1998 3
1999 2
2000 1
2001 2
2002 1
2003 2
2004 5
2005 2
2006 3
2007 5
2008 7
2009 6
2010 5
2011 12
2012 9
2013 10
2014 12
2015 13
2016 24
2017 19
2018 20
2019 15
2020 19
2021 18
2022 25
2023 18
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Results by year

Filters applied: . Clear all
Page 1
[Groundbreaking basic research].
Helland Å. Helland Å. Tidsskr Nor Laegeforen. 2018 Dec 10;138(20). doi: 10.4045/tidsskr.18.0802. Print 2018 Dec 11. Tidsskr Nor Laegeforen. 2018. PMID: 30539600 Free article. Norwegian. No abstract available.
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Planchard D, et al. Among authors: helland a. Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11. Lancet Oncol. 2017. PMID: 28919011 Clinical Trial.
Immune Cell Composition in Human Non-small Cell Lung Cancer.
Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, Hammarström C, Beraki K, Bækkevold ES, Woldbæk PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A. Stankovic B, et al. Among authors: helland a. Front Immunol. 2019 Feb 1;9:3101. doi: 10.3389/fimmu.2018.03101. eCollection 2018. Front Immunol. 2019. PMID: 30774636 Free PMC article.
Hever kvaliteten på behandling av kreft.
Helland Å, Steinskog ESS, Blix ES, Flobak Å, Brabrand S, Puco K, Niehusmann P, Meltzer S, Oppedal IA, Haug Å, Torkildsen CF, Randen U, Gilje B, Lønning PE, Gjertsen BT, Hovland R, Russnes HG, Fagereng GL, Smeland S, Tasken K. Helland Å, et al. Tidsskr Nor Laegeforen. 2024 Jan 18;144(1). doi: 10.4045/tidsskr.23.0740. Print 2024 Jan 23. Tidsskr Nor Laegeforen. 2024. PMID: 38258713 Free article. Norwegian. No abstract available.
Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms.
Lehtiö J, Arslan T, Siavelis I, Pan Y, Socciarelli F, Berkovska O, Umer HM, Mermelekas G, Pirmoradian M, Jönsson M, Brunnström H, Brustugun OT, Purohit KP, Cunningham R, Foroughi Asl H, Isaksson S, Arbajian E, Aine M, Karlsson A, Kotevska M, Gram Hansen C, Drageset Haakensen V, Helland Å, Tamborero D, Johansson HJ, Branca RM, Planck M, Staaf J, Orre LM. Lehtiö J, et al. Among authors: helland a. Nat Cancer. 2021 Nov;2(11):1224-1242. doi: 10.1038/s43018-021-00259-9. Epub 2021 Nov 22. Nat Cancer. 2021. PMID: 34870237 Free PMC article.
Nye anbefalinger ved serumkonsentrasjonsmålinger av sentralstimulerende legemidler.
Frost J, Bernard JP, Dietrichs ES, Kjeldstadli K, Riedel B, Skråstad RB, Vevelstad M, Helland A. Frost J, et al. Among authors: helland a. Tidsskr Nor Laegeforen. 2019 Sep 23;139(13). doi: 10.4045/tidsskr.19.0385. Print 2019 Sep 24. Tidsskr Nor Laegeforen. 2019. PMID: 31556515 Free article. Norwegian. No abstract available.
Establishing Serum Reference Ranges for Antihypertensive Drugs.
Rognstad S, Søraas CL, Bergland OU, Høieggen A, Strømmen M, Helland A, Opdal MS. Rognstad S, et al. Among authors: helland a. Ther Drug Monit. 2021 Feb 1;43(1):116-125. doi: 10.1097/FTD.0000000000000806. Ther Drug Monit. 2021. PMID: 32881780 Review.
A national precision cancer medicine implementation initiative for Norway.
Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES; CONNECT Public–Private Partnership Consortium; Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R; InPreD-Norway and National Molecular Tumor Board Consortium; IMPRESS-Norway Consortium; Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å. Taskén K, et al. Among authors: helland a. Nat Med. 2022 May;28(5):885-887. doi: 10.1038/s41591-022-01777-4. Nat Med. 2022. PMID: 35513529 No abstract available.
Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial.
Rakaee M, Andersen S, Giannikou K, Paulsen EE, Kilvaer TK, Busund LR, Berg T, Richardsen E, Lombardi AP, Adib E, Pedersen MI, Tafavvoghi M, Wahl SGF, Petersen RH, Bondgaard AL, Yde CW, Baudet C, Licht P, Lund-Iversen M, Grønberg BH, Fjellbirkeland L, Helland Å, Pøhl M, Kwiatkowski DJ, Donnem T. Rakaee M, et al. Among authors: helland a. Ann Oncol. 2023 Jul;34(7):578-588. doi: 10.1016/j.annonc.2023.04.005. Epub 2023 Apr 24. Ann Oncol. 2023. PMID: 37100205 Free article.
Whole Exome Library Construction for Next Generation Sequencing.
Liang WS, Stephenson K, Adkins J, Christofferson A, Helland A, Cuyugan L, Keats JJ. Liang WS, et al. Among authors: helland a. Methods Mol Biol. 2018;1706:163-174. doi: 10.1007/978-1-4939-7471-9_9. Methods Mol Biol. 2018. PMID: 29423798 Review.
256 results